HC Wainwright Reaffirms “Hold” Rating for Oncomed Pharmaceuticals (OMED)
Oncomed Pharmaceuticals (NASDAQ:OMED)‘s stock had its “hold” rating reiterated by stock analysts at HC Wainwright in a report issued on Friday. They presently have a $3.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s price objective points to a potential downside of 8.81% from the stock’s current price.
Several other equities analysts have also issued reports on OMED. Zacks Investment Research lowered shares of Oncomed Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, January 6th. Cantor Fitzgerald set a $6.00 price target on shares of Oncomed Pharmaceuticals and gave the company a “hold” rating in a report on Thursday, January 4th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and one has assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $5.44.
Oncomed Pharmaceuticals (OMED) opened at $3.29 on Friday. Oncomed Pharmaceuticals has a fifty-two week low of $1.74 and a fifty-two week high of $10.42.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Hodges Capital Management Inc. boosted its stake in Oncomed Pharmaceuticals by 155.9% in the 3rd quarter. Hodges Capital Management Inc. now owns 25,592 shares of the biopharmaceutical company’s stock worth $116,000 after purchasing an additional 15,592 shares during the period. BlueCrest Capital Management Ltd acquired a new position in Oncomed Pharmaceuticals in the 4th quarter worth $133,000. Paloma Partners Management Co acquired a new position in Oncomed Pharmaceuticals in the 4th quarter worth $135,000. Virtu Financial LLC acquired a new position in Oncomed Pharmaceuticals in the 4th quarter worth $170,000. Finally, Goldman Sachs Group Inc. boosted its stake in Oncomed Pharmaceuticals by 89.8% in the 4th quarter. Goldman Sachs Group Inc. now owns 52,106 shares of the biopharmaceutical company’s stock worth $214,000 after purchasing an additional 24,653 shares during the period. 53.57% of the stock is owned by hedge funds and other institutional investors.
WARNING: This piece was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2018/03/11/hc-wainwright-reaffirms-hold-rating-for-oncomed-pharmaceuticals-omed.html.
Oncomed Pharmaceuticals Company Profile
OncoMed Pharmaceuticals, Inc (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer’s growth, resistance, recurrence and metastasis. The Company’s therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11).
Receive News & Ratings for Oncomed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncomed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.